Drugs / CKD-393
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05274880 | Jun → Jul 2022 | type 2 diabetes mellitus | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT05113693 | Nov → Dec 2021 | type 2 diabetes mellitus | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT04768673 | Mar → Apr 2021 | type 2 diabetes mellitus | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT04706286 | Feb → Mar 2021 | type 2 diabetes mellitus | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 1 | NCT04260438 | Apr → Jun 2020 | type 2 diabetes mellitus | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CKD-393 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05274880 ↗ |
| Route | Oral | “single oral administration under fed condition” NCT04260438 ↗ |